KARAM BIOSCIENCE
Enterprise Evidence Data
Public scope outline / 2026-10-15

Proposed research work, not an accepted engagement or demonstrated result.

DECISION
The proposed enterprise product is a permissioned dataset with a documented schema, original annotations and provenance. Its value would come from consistent experimental context and usable rights, not a claim to own public facts. A data product must exist and pass customer tests before a paid API or annual license is offered.

READINESS
Data product in development

PLANNING BUDGET; NOT A QUOTE
$15,000–$50,000 annual pilot proposed

TIMING CONDITION
Only after a usable, permissioned dataset exists

DELIVERABLES
Schema and field definitions: Source identifiers, dates, study model, endpoints, limitations and documented missingness.
Permissioned delivery: Contracted internal-use or integration rights and a clear distinction between annotations, public facts and third-party content.
Versioned records: Release identifiers and change handling so downstream applications can reproduce their evidence inputs.
Pilot acceptance tests: A sample dataset and agreed retrieval, coverage or integration tasks before annual access is expanded.

INPUTS
The integration use case, fields, anticipated users, export or API needs, rights requirements and a test dataset specification.

ACCEPTANCE
Rights-cleared records and demonstrated usefulness on agreed tasks. No endpoint or service-level commitment is assumed until a working pilot is delivered.

BOUNDARIES
No live paid API is currently advertised as operating. No right to republish copyrighted articles, no guaranteed completeness and no ownership claim over public facts.